摘要
目的观察恩替卡韦辅治失代偿期乙肝肝硬化患者的临床效果。方法将100例失代偿期乙肝肝硬化患者随机分为治疗组和对照组各50例。对照组患者采用常规的治疗方法,治疗组在常规治疗方法的基础上联合恩替卡韦治疗。比较2组治疗前和治疗后第12、24周的血清丙氨酸氨基转移酶(ALT)、天门冬氨酸基转移酶(AST)、总胆红素(TBIL)水平和Child-Pugh评分。结果治疗前2组ALT、AST、TBIL水平和Child-Pugh评分差异无统计学意义(P>0.05)。在治疗后12周和24周,2组ALT、AST、TBIL水平和Child-Pugh的评分均低于治疗前,且治疗组低于对照组,差异均有统计学意义(P<0.05或P<0.01)。结论对于失代偿期乙肝肝硬化患者加用恩替卡韦治疗,临床效果显著,能够有效改善患者肝功能,预防并发症,安全性较高,值得临床推广应用,以帮助更多患者受益。
ObjectiveToobservetheclinicaleffectofentecavirindecompensatedcirrhosis.Methods 100cases patients with decompensated cirrhosis were randomly divided into treatment group and control group ,each of 50 cases.Control group accepted conventional treatment .Treatment group was treated , on the bases of control group , by entecavir .After treat-ment,compared the level of ALT、AST、TBIL and Child-pugh score before and after treatment .Results The level of ALT、AST、TBIL and Child-Pugh score in 2 groups has no statistically significant （P〉0.05）.After 12、24 weeks treatment,the level of ALT、AST、TBIL and Child-Pugh score in 2 groups were lower than that before treatment ,and the level of ALT、AST、TBIL and Child-Pugh score of treatment group was lower than that of control group （P〈0.05 or P〈0.01）.Conclusion Entecavir in decompensated cirrhosis has an good effect , can significant improvement in renal functionprevent complications and safe . Worthy of clinical application to help more patients benefit .
出处
《临床合理用药杂志》
2015年第19期9-10,共2页
Chinese Journal of Clinical Rational Drug Use
